A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia
CONCLUSIONS: An immune-ERG-based risk model was developed to effectively predict prognostic outcomes for AML patients. There is potential for immune therapy in AML targeting the five hub genes.PMID:38186215 | DOI:10.1080/16078454.2023.2300855
Source: Hematology - Category: Hematology Authors: Zenghui Fang Jiali Fu Xin Chen Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Genetics | Hematology | Leukemia | Study